Tatiana Novobrantseva

Company: Moderna

Job title: Chief Scientific Officer, Immuno-Oncology Research

Seminars:

Panel Discussion:Adoptive Cell Therapy vs CD47 vs Repolarization: Exploring Potential for Each Mechanism to Influence Indication Selection 2:00 pm

Comparing targeting abilities of various macrophage targeted therapies to identify benefits and limitations Discussing characteristics of various indications to evaluate where each modality may be beneficial Highlighting where these different therapies could be applied to regenerative medicine and inflammatory diseaseRead more

day: Day Two

Leaders’ Fireside Chat:The Potential of Macrophage Therapies & Securing a Successful Future 9:00 am

Consolidating clinical advances and robust data from the past year to instill in vivo proof of efficacy Identifying preclinical programs with exciting potential and novel strategies to target macrophages Reviewing current hurdles the field is facing, in research as well as funding, and plotting methods to increase awareness and investment into the spaceRead more

day: Day Two